-
Texas Cardiac Arrhythmia Institute leader participates in clinical trial for world's first artificial intelligence technology for complex cardiac arrhythmia procedures
prnasia
July 23, 2021
The leader of the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently led a clinical study to evaluate the world's first data-driven artificial intelligence (AI) platform for cardiac electrophysiology (EP) procedures.
-
Digital New Deal Startups Gain Global Attention
prnasia
July 20, 2021
The Born2Global Centre released an article that highlights the Ministry of Science and ICT (MSIT)'s effort to support technology startups, included in the Korean Digital New Deal.
-
AI and big data will continue to disrupt pharma sector, says survey
europeanpharmaceuticalreview
July 20, 2021
A GlobalData report has revealed the extent to which companies will be using AI and big data in drug discovery and development processes.
-
AI, big data will continue to disrupt pharma sector, say healthcare industry professionals in GlobalData survey
expresspharma
July 19, 2021
The COVID-19 pandemic has given businesses an unprecedented opportunity to implement technology-fueled changes to the way they operate.
-
Artificial intelligence could be new blueprint for precision drug discovery
worldpharmanews
July 13, 2021
Writing in the July 12, 2021 online issue of Nature Communications, researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is ...
-
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms
prnasia
July 12, 2021
I-Mab announced the signing of two new collaborations with emerging biotech companies in China to strengthen its next-generation innovation pipeline.
-
Kuano raises £1m to further develop AI drug discovery platform
pharmatimes
July 09, 2021
London-headquartered artificial intelligence company Kuano has raised £1m in seed funding to accelerate the development of its platform, focused on transforming the discovery of therapeutics targeting enzyme inhibition.
-
Exscientia receives $1.5m Gates Foundation grant for AI-designed Covid-19 drugs
pharmaceutical-technology
July 09, 2021
UK-based artificial intelligence (AI) drug discovery company Exscientia has received a $1.5m grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners to accelerate the development of a new class of Covid-19 drugs.
-
Standigm Secures $10 M From Pavilion Capital to Accelerate Its Global Competitiveness
firstwordpharma
July 07, 2021
Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that they have secured a $10 million investment from Pavilion Capital, a Singapore-based investment institution.
-
Exscientia signs $1.2bn AI drug discovery deal with BMS
pharmaceutical-technology
May 21, 2021
Bristol-Myers Squibb (BMS) and Exscientia have signed a partnership agreement to leverage artificial intelligence (AI) for the discovery of small molecule drug candidates in various therapeutic areas, including oncology and immunology.